Page 21 - Hal Barron News Today

GlaxoSmithKline and Vir Biotechnology to expand antibody collaboration

New Wonder Drug Successful in Treating COVID-19 A new Covid-19 drug has been found to prevent 100 per cent of symptomatic infections during trials on the NHS. The promising results suggest that the experimental antibody cocktail, developed by Regeneron Pharmaceuticals Inc, could be used as a “passive vaccine” to block coronavirus. Patients who took part in the trial, run with the National Institute of Allergy and Infectious Diseases (NIAID), were injected with the antibody cocktail, called ...

Updated The drug has been found to prevent 100 per cent of symptomatic infections (Photo: Shutterstock) A new Covid-19 drug has been found to prevent 100 per cent of symptomatic infections during trials carried out by the NHS. The promising results suggest that the experimental antibody cocktail, developed by Regeneron Pharmaceuticals Inc, could be used as a “passive vaccine” to block coronavirus. Reduced overall infections Patients who took part in the trial, run with the National Institu...

Two Covid-19 antibody treatments from different companies combined in new study Study to combine two Covid-19 antibody treatments from different companies (Andy Buchanan/PA) A new clinical study is being launched to see whether two Covid-19 antibody treatments made by different pharmaceutical companies can be combined to improve patient outcomes. British drugs firm GlaxoSmithKline (GSK) and clinical-stage immunology company Vir Biotechnology’s treatment, known as VIR-7831, will be given to lo...

Share this article Share this article INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as...

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours GlaxoSmithKline’s (GSK) dostarlimab – an investigational PD-1 inhibitor – has demonstrated promising results in patients with heavily pre-treated solid cancer tumours. The updated data comes from cohort F of GSKs GARNET trial, which enrolled patients with mismatch repair-deficient (dMMR) non-endometrial advanced solid ca...

Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year. Preclinical data suggests VIR-7832, a neutralising COVID-19 antibody, has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent CO...

One of Britain’s biggest drugs companies said yesterday that it had more than ten potential blockbuster treatments in the late stages of development.Hal Barron, chief scientific officer and head of

GlaxoSmithKline (GSK), along with Vir Biotechnology, has agreed with the UK-based AGILE initiative to assess VIR-7832 in patients with Covid-19

On a day of major developments, Glaxosmithkline said it was joining an NHS study to test a breakthrough antibody treatment. The drug - known as Vir-7832 -could be a game changer.